Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.

Annals of surgical oncology - 1 Mar 2007

Yeh Chun-Nan, Chen Tsung-Wen, Lee Hsiang-Lin, Liu Yu-Yin, Chao Tzu-Chieh, Hwang Tsann-Long, Jan Yi-Yin, Chen Miin-Fu

Abstract excerpt

PURPOSE: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutation of kit or platelet-derived growth factor receptor alpha (PDGFRA), which are therapeutic targets for imatinib. Results of 64 Taiwanese with advanced GIST treated with imatinib were reported. METHOD AND MATERIALS: Between 2001 and May 2006, a prospective, non-randomized, and a single center trial containing 64 Taiwanese...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Taiwan

Source

Identifiers

PMID: 17195905
DOI: 10.1245/s10434-006-9288-1

Genes

PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.PMID 17195905Read ↗

Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.Semantic proximity Read ↗

The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.Semantic proximity Read ↗

Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.Semantic proximity Read ↗

Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.Semantic proximity Read ↗

Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.Semantic proximity Read ↗

C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.Semantic proximity Read ↗

Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

[Clinical analysis of imatinib in patients with advanced gastrointestinal stromal tumor].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.